[{"orgOrder":0,"company":"National Jewish Health","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ Astellas Pharma"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Colistin Sulfate","moa":"Cell outer membrane","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"National Jewish Health \/ AstraZeneca"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"University of Alabama at Birmingham | Children's Hospital of Philadelphia | Johns Hopkins University | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Glycerol Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Liquid","sponsorNew":"National Jewish Health \/ University of Alabama at Birmingham | Children's Hospital of Philadelphia | Johns Hopkins University | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Jewish Health \/ University of Alabama at Birmingham | Children's Hospital of Philadelphia | Johns Hopkins University | Amgen Inc"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"American Thoracic Society","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ American Thoracic Society","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ American Thoracic Society"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"National Jewish Health \/ Genentech"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Reslizumab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ AstraZeneca"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Augusta University | Cystic Fibrosis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Jewish Health \/ Augusta University | Cystic Fibrosis Foundation","highestDevelopmentStatusID":"9","companyTruncated":"National Jewish Health \/ Augusta University | Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AZD7624","moa":"Stress-activated protein kinase (p38)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Saracatinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research","highestDevelopmentStatusID":"7","companyTruncated":"National Jewish Health \/ Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Dog Hair Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ ALK","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ ALK"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Endotoxin","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Hypnotic Medication Taper","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PPV-23","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Rhdnase","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"National Jewish Health \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by National Jewish Health
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
